Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.81 CAD
Change Today +0.03 / 3.85%
Volume 30.1K
As of 1:16 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

spectral medical inc (EDT) Snapshot

Open
C$0.82
Previous Close
C$0.78
Day High
C$0.82
Day Low
C$0.78
52 Week High
04/14/15 - C$1.18
52 Week Low
01/16/15 - C$0.27
Market Cap
154.7M
Average Volume 10 Days
161.0K
EPS TTM
C$-0.04
Shares Outstanding
191.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRAL MEDICAL INC (EDT)

Related News

No related news articles were found.

spectral medical inc (EDT) Related Businessweek News

No Related Businessweek News Found

spectral medical inc (EDT) Details

Spectral Medical Inc. focuses on the development and commercialization of theranostic treatment for severe sepsis in North America. The company’s products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It is also involved in the development, production, and marketing of recombinant cardiac proteins, antibodies, and calibrators for use in research and development, as well as in products manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.

19 Employees
Last Reported Date: 03/25/15
Founded in 1991

spectral medical inc (EDT) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: C$426.0K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: C$266.2K
Vice President of Clinical Development
Total Annual Compensation: C$202.3K
Vice President of Sales and Marketing
Total Annual Compensation: C$185.8K
Compensation as of Fiscal Year 2014.

spectral medical inc (EDT) Key Developments

Spectral Medical Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2015

Spectral Medical Inc. announced unaudited financial results for the second quarter and six months ended June 30, 2015. For the second quarter, revenue was CAD 818,000 compared to CAD 778,000 for the same period in the preceding year. Loss was CAD 2,366,000 or CAD 0.01 per basic and diluted share compared to a loss of CAD 2,451,000 or CAD 0.02 per basic and diluted share for the three months ended June 30, 2014. Operating loss was CAD 2,390,000 compared to CAD 2,451,000 a year ago. For the six months ended June 30, 2015 revenues were CAD 1,695,000 compared to CAD 1,622,000 in the first half of 2014. Revenues for both the quarter and the year were consistent with prior year levels and this trend is expected to continue for the remainder of the year. Loss was CAD 4,631,000 or CAD 0.02 per basic and diluted share compared to CAD 5,626,000 or CAD 0.04 per basic and diluted share for the same six month period in the prior year. Operating loss was CAD 4,679,000 compared to CAD 5,640,000 a year ago. Net cash used in operating activities was CAD 5,025,000 compared to CAD 5,774,000 a year ago. Property and equipment expenditure was CAD 191,000 compared to CAD 14,000 a year ago.

Spectral Medical Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 08:00 AM

Spectral Medical Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 08:00 AM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States.

Spectral Medical Inc. Announces Unaudited Financial Results for the First Quarter Ended March 31, 2015

Spectral Medical Inc. announced unaudited financial results for the first quarter ended March 31, 2015. For the first quarter, the company’s revenue for the three months ended March 31, 2015 was CAD 877,000 compared to CAD 844,000 for the same period in the preceding year. First quarter revenues were consistent with prior year levels and this trend is expected to continue for the remainder of the year. Operating loss was CAD 2,289,000 against CAD 3,189,000 a year ago. Loss and comprehensive loss for the quarter ended March 31, 2015 was CAD 2,265,000 or CAD 0.01 per basic and diluted share compared to CAD 3,175,000 or CAD 0.02 per basic and diluted share for the same quarter last year. Net cash used in operating activities was CAD 2,856,000 against CAD 3,497,000 a year ago. Property and equipment expenditures were CAD 118,000 against CAD 2,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EDT:CN C$0.81 CAD +0.03

EDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EDT.
View Industry Companies
 

Industry Analysis

EDT

Industry Average

Valuation EDT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 46.4x
Price/Book 13.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 42.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRAL MEDICAL INC, please visit www.spectraldx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.